In pancreatic cancer specifically, patient-derived models such as organoids and xenografts have allowed for a more nuanced understanding of the tumor’s heterogeneity, offering insights into how genetic mutations, such as those in the Smad4 gene, contribute to tumor growth and resistance to therapy. This evidence concerns the gene SMAD4 and familial pancreatic carcinoma.